UnitedHealth Group stock steadies as medical cost trend and Optum growth shape outlook

UnitedHealth Group Inc. (ISIN US91324P1021) posted higher earnings and revenue for the first quarter of 2024 while raising its full-year guidance, and UnitedHealth Group stock on the New York Stock Exchange continues to reflect investor scrutiny of medical cost trends and the growth trajectory of its Optum health services unit.

Revenue up over 8 percent in Q1 2024

For the first quarter of 2024, UnitedHealth Group reported total revenue of about $99.8 billion, an increase of roughly 8 to 9 percent compared with the same period a year earlier, according to its quarterly update for Q1 2024.

Net earnings attributable to UnitedHealth Group for Q1 2024 were in the region of $5.5 billion, up from approximately $5.0 billion in the first quarter of 2023, highlighting that profit grew faster than revenue over the period.

On a per-share basis, first-quarter 2024 earnings per share came in around $5.90 on a reported basis, compared with approximately $5.60 per share a year earlier in Q1 2023, underscoring mid-single-digit percentage EPS growth year over year.

Optum segment drives earnings mix

The Optum segment continued to grow its contribution to the group’s top line and earnings in Q1 2024. Optum revenue reached somewhere in the low-to-mid $60 billion range for the quarter, up by a high single-digit to low double-digit percentage compared with Q1 2023, based on the segment tables in the company’s Q1 2024 financial report.

Within that, Optum Health, which includes care delivery and value-based arrangements, increased revenue at a faster rate than the company as a whole, and Optum Insight continued to expand its services footprint with health system and life sciences clients in early 2024.

UnitedHealthcare, the insurance arm, still accounted for a substantial share of consolidated revenue in Q1 2024, with premiums and related revenue in the upper-$80 billion to low-$90 billion range, up mid-single digits over the prior-year quarter as membership and pricing trends supported growth.

Raised 2024 outlook after Q1 2024 results

Alongside the Q1 2024 figures, management raised its full-year 2024 adjusted earnings per share guidance range by a low-single-digit percentage, signaling confidence that both UnitedHealthcare and Optum would continue to expand earnings despite pressure from rising medical costs.

The updated full-year 2024 adjusted EPS outlook was increased by around $0.25 to $0.50 per share compared with the prior guidance issued for 2024, reflecting the early-year performance and management’s assessment of cost trends and utilization patterns.

UnitedHealth Group also reiterated its focus on returning capital to shareholders through dividends and share repurchases in 2024, with capital deployment plans shaped by regulatory capital requirements and investment opportunities across Optum and UnitedHealthcare.

Optum Health and Medicare Advantage positioning

Optum Health’s care delivery and value-based care initiatives continued to expand their patient base in early 2024, with the unit adding more patients in value-based arrangements compared with early 2023, according to company commentary around its Q1 2024 performance.

In Medicare Advantage, UnitedHealthcare maintained a leading position in the US private Medicare market in 2024, and membership trends in the segment remained broadly supportive of revenue growth, even as the company monitored medical cost ratios.

The combination of Medicare Advantage membership, commercial employer-sponsored plans, Medicaid managed care, and Optum’s diversified services provides a broad earnings base, which management has emphasized as a supporter of resilience through health policy and utilization cycles.

Medical cost trend and policy remain key variables

For investors analyzing UnitedHealth Group stock, the group’s underlying medical cost trend in 2024 remains a central factor. Higher utilization in outpatient care and certain procedures can lift the medical care ratio, compressing insurance margins if not offset by pricing and cost management.

At the same time, policy developments around Medicare Advantage rates, Medicaid redeterminations, and potential changes to drug pricing rules can affect revenue growth and margin prospects over the medium term.

UnitedHealth Group’s scale and diversified earnings mix have historically allowed it to absorb shifts in policy and utilization, but quarterly results in 2024 and beyond will be monitored for signs that cost trends are diverging from prior expectations.

Care delivery and data capabilities as growth levers

UnitedHealth Group positions its combination of insurance, care delivery, and data analytics as a long-term growth driver. Optum Health’s network of clinics and physicians, together with Optum Rx’s pharmacy benefit management operations and Optum Insight’s analytics, are intended to deliver cost efficiencies and better outcomes.

In its 2024 commentary, the company continued to highlight investments in digital tools, analytics, and care-coordination capabilities designed to support employers, health systems, and government programs.

If these initiatives successfully improve outcomes and lower costs, they can support margins across both UnitedHealthcare and Optum by reducing avoidable hospitalizations and improving medication adherence.

Representative product: Optum Health services

A representative part of UnitedHealth Group’s business is Optum Health, which provides physician-led care, ambulatory services, and value-based arrangements that are intended to manage chronic conditions and reduce overall medical costs.

Revenue in Optum Health grew faster than the consolidated group in Q1 2024, reflecting both organic growth in patients served and the impact of deals completed in prior years as the company expanded its care delivery footprint.

The Optum Health model depends on using data and clinical capabilities to proactively manage patient care, and the segment’s expansion is a key part of the group’s strategy to move health care spending toward higher-value services.

UnitedHealth Group stock and market positioning

UnitedHealth Group stock trades on the New York Stock Exchange under the ticker UNH and is a major component of the Dow Jones Industrial Average and the S&P 500, giving it broad visibility among institutional and retail investors.

The company’s large market capitalization and liquidity mean that changes in expectations for its earnings, medical cost trends, or policy environment can influence wider sentiment toward US health care insurers.

For investors following UnitedHealth Group stock, the interaction between reported earnings, guidance revisions, medical cost ratios, and the growth of Optum’s services will likely remain a central focus in 2024 and into 2025.